Poly-(ADP-ribose)-polymerase inhibitors as radiosensitizers: a systematic review of pre-clinical and clinical human studies

Poly-(ADP-Ribose)-Polymerase (PARP) inhibitors are becoming important actors of anti-neoplasic agents landscape, with recent but narrow FDA's approvals for ovarian BRCA mutated cancers and prostatic cancer. Nevertheless, PARP inhibitors are also promising drugs for combined treatments particula...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Oncotarget 2017-09, Vol.8 (40), p.69105-69124
Hauptverfasser:	Lesueur, Paul, Chevalier, François, Austry, Jean-Baptiste, Waissi, Waisse, Burckel, Hélène, Noël, Georges, Habrand, Jean-Louis, Saintigny, Yannick, Joly, Florence
Format:	Artikel
Sprache:	eng
Schlagworte:	Cancer Life Sciences Review
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!